本妥昔单抗：临床进展与实用指南
Brentuximab vedotin: clinical updates and practical guidance.
作者信息
Yi Jun Ho, Kim Seok Jin, Kim Won Seog
机构信息
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Blood Res. 2017 Dec;52(4):243-253. doi: 10.5045/br.2017.52.4.243. Epub 2017 Dec 26.
Abstract
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
摘要
本妥昔单抗（BV）是一种强效抗体药物偶联物，靶向CD30抗原。由于在CD30阳性淋巴瘤（如霍奇金淋巴瘤和系统性间变性大细胞淋巴瘤）中显示出显著疗效，BV于2011年获得美国食品药品监督管理局加速批准。此后，在各种情况下进行了许多大规模试验，从而扩大了最初的适应证范围。本综述的目的是描述BV临床试验的最新进展以及BV使用的实际指导。
相似文献
1
Brentuximab vedotin: clinical updates and practical guidance.
Blood Res. 2017 Dec;52(4):243-253. doi: 10.5045/br.2017.52.4.243. Epub 2017 Dec 26.
2
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.
3
Brentuximab vedotin in systemic T-cell lymphoma.
Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.
4
Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
BMC Cancer. 2018 Feb 1;18(1):122. doi: 10.1186/s12885-018-4042-1.
5
Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Expert Rev Anticancer Ther. 2016;16(3):279-83. doi: 10.1586/14737140.2016.1146597. Epub 2016 Feb 18.
6
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
7
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
Onco Targets Ther. 2013 Dec 19;7:45-56. doi: 10.2147/OTT.S39107.
8
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.
9
Brentuximab vedotin for the treatment of CD30+ lymphomas.
Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15.
10
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Future Oncol. 2017 Nov;13(27):2405-2411. doi: 10.2217/fon-2017-0263. Epub 2017 Aug 14.
引用本文的文献
1
Treatment of Methotrexate-Associated Lymphoproliferative Disorder With Biological Therapies.
Cureus. 2025 Jan 1;17(1):e76751. doi: 10.7759/cureus.76751. eCollection 2025 Jan.
2
Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation.
Sci Rep. 2025 Jan 13;15(1):1824. doi: 10.1038/s41598-024-84744-y.
3
Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression.
Onco Targets Ther. 2025 Jan 6;18:1-14. doi: 10.2147/OTT.S487088. eCollection 2025.
4
Electrophysiological Studies in Combination With Interim-Positron Emission Tomography Scan for Prevention of Severe Brentuximab-Vedotin-Induced Neurotoxicity.
Eur J Haematol. 2025 May;114(5):802-811. doi: 10.1111/ejh.14384. Epub 2025 Jan 7.
5
Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms.
Front Immunol. 2024 Dec 17;15:1520103. doi: 10.3389/fimmu.2024.1520103. eCollection 2024.
6
Advances in CAR-T-cell therapy in T-cell malignancies.
J Hematol Oncol. 2024 Jun 24;17(1):49. doi: 10.1186/s13045-024-01568-z.
7
Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.
Mediterr J Hematol Infect Dis. 2024 Mar 1;16(1):e2024015. doi: 10.4084/MJHID.2024.015. eCollection 2024.
8
Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.
Cureus. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. eCollection 2024 Jan.
9
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.
J Clin Med. 2024 Jan 31;13(3):823. doi: 10.3390/jcm13030823.
10
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
Blood Res. 2023 Dec 31;58(4):194-200. doi: 10.5045/br.2023.2023206. Epub 2023 Nov 30.
本文引用的文献
1
Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Oncologist. 2016 Dec;21(12):1436-1441. doi: 10.1634/theoncologist.2016-0112. Epub 2016 Aug 2.
2
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25.
3
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.
4
Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin's Lymphoma.
Case Rep Pulmonol. 2016;2016:2359437. doi: 10.1155/2016/2359437. Epub 2016 Apr 17.
5
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Br J Clin Pharmacol. 2016 Sep;82(3):696-705. doi: 10.1111/bcp.12988. Epub 2016 May 29.
6
Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
Clin Adv Hematol Oncol. 2016 Feb;14(2 Suppl 1):13-5.
7
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
Haematologica. 2016 Apr;101(4):466-73. doi: 10.3324/haematol.2015.134213. Epub 2016 Jan 14.
8
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24.
9
Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
Cancer Lett. 2016 Sep 28;380(1):243-52. doi: 10.1016/j.canlet.2015.10.007. Epub 2015 Oct 23.
10
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Blood. 2015 Dec 24;126(26):2798-804. doi: 10.1182/blood-2015-06-644336. Epub 2015 Sep 16.
Zotero 插件